Literature DB >> 19602328

Treatment of hypertension in patients with peripheral arterial disease: an update.

Denis L Clement1.   

Abstract

Hypertension is a known risk factor for cardiovascular events, and recent data have pointed to peripheral arterial disease (PAD) as another strong risk factor; together, they cause a surprisingly high total risk. This review deals with the clinical management of this dangerous association. The ankle-brachial index helps in the diagnosis of PAD and the estimation of risk. To control risk, lifestyle adaptation is essential. There is no consensus on a first choice of antihypertensive drug. Arguments favor angiotensin-converting enzyme inhibitors, but most patients require several antihypertensive drugs to reach goal pressure (140/90 mm Hg or lower). Moreover, to control the risk of PAD, antiplatelet drugs, antihypertensive drugs, and statins are recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602328     DOI: 10.1007/s11906-009-0046-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  43 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  The fate of the claudicant--a prospective study of 1969 claudicants.

Authors:  J A Dormandy; G D Murray
Journal:  Eur J Vasc Surg       Date:  1991-04

3.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

4.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

5.  Diagnosis and treatment of peripheral arterial disease: recommendations for the medical practice in Belgium.

Authors:  Denis Clement; Philippe Kolh; Serge Motte; Muriel Sprynger; Hendrik Van Damme; Peter Verhamme; Frank Vermassen; Jean-Claude Wautrecht
Journal:  Acta Chir Belg       Date:  2007 Nov-Dec       Impact factor: 1.090

6.  Association of low ankle brachial index with high mortality in primary care.

Authors:  Curt Diehm; Stefan Lange; Harald Darius; David Pittrow; Berndt von Stritzky; Gerhart Tepohl; Roman L Haberl; Jens Rainer Allenberg; Burkhard Dasch; Hans Joachim Trampisch
Journal:  Eur Heart J       Date:  2006-06-16       Impact factor: 29.983

7.  Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.

Authors:  A Haenni; H Lithell
Journal:  J Hypertens Suppl       Date:  1999-08

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

9.  Natural history and evolution of peripheral obstructive arterial disease.

Authors:  D Duprez
Journal:  Int Angiol       Date:  1992 Jul-Sep       Impact factor: 2.789

10.  Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication.

Authors:  M G Bogaert; D L Clement
Journal:  Eur Heart J       Date:  1983-03       Impact factor: 29.983

View more
  2 in total

Review 1.  Peripheral artery disease. Part 2: medical and endovascular treatment.

Authors:  Mitchell D Weinberg; Joe F Lau; Kenneth Rosenfield; Jeffrey W Olin
Journal:  Nat Rev Cardiol       Date:  2011-06-14       Impact factor: 32.419

2.  Cohort Study Examining the Association Between Blood Pressure and Cardiovascular Events in Patients With Peripheral Artery Disease.

Authors:  Diana Thomas Manapurathe; Joseph Vaughan Moxon; Smriti Murali Krishna; Sophie Rowbotham; Frank Quigley; Jason Jenkins; Michael Bourke; Bernard Bourke; Rhondda E Jones; Jonathan Golledge
Journal:  J Am Heart Assoc       Date:  2019-03-19       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.